Monday, July 25, 2016

BRIEF-Spark Therapeutics and Pfizer announce data from first cohort in Hemophilia B Phase 1/2 trial

* Spark Therapeutics and Pfizer announce updated data from

first cohort in Hemophilia B phase 1/2 trial demonstrating

consistent, sustained therapeutic levels of factor ix activity

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)